Unknown

Dataset Information

0

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics.


ABSTRACT: Background:Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play only a minor role in hemostasis and is therefore an attractive anticoagulant drug target. Objectives:To evaluate the safety, pharmacodynamic, and pharmacokinetic properties of BAY 1213790, a fully human immunoglobulin (Ig) G1 antibody targeting activated coagulation FXI (FXIa), in healthy men. Methods:In this phase 1, single-blind, parallel-group, placebo-controlled, dose-escalation study, 83 healthy Caucasian men were randomized 4:1 to receive a single 60-minute intravenous infusion of BAY 1213790 (0.015-10 mg/kg) or placebo. Adverse events, pharmacodynamic parameters (including activated partial thromboplastin time [aPTT]) and pharmacokinetic parameters were determined. Volunteers were followed up for 150 days. Results:BAY 1213790 demonstrated favorable safety and tolerability; there were no observed cases of bleeding or clinically relevant antidrug antibody formation. One volunteer (1.2%) experienced an infusion reaction. Following intravenous administration of BAY 1213790, dose-dependent increases in aPTT (maximal mean increase relative to baseline: 1.85 [conventional method] and 2.17 [kaolin-triggered method]) and rotational thromboelastometry whole blood clotting time were observed, as well as dose-dependent reductions in FXI activity. Bleeding times did not increase following administration of BAY 1213790 and were similar for all dose cohorts, including placebo. Measurable and dose-dependent increases in systemic exposure were detected for all doses of BAY 1213790 of 0.06 mg/kg or higher. Conclusions:Based on these safety, pharmacodynamic, and pharmacokinetic results, further evaluation of BAY 1213790 in patients with, or at risk of, thrombosis is warranted.

SUBMITTER: Thomas D 

PROVIDER: S-EPMC6462747 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics.

Thomas Dirk D   Thelen Kirstin K   Kraff Stefanie S   Schwers Stephan S   Schiffer Sonja S   Unger Sigrun S   Yassen Ashraf A   Boxnick Stefanie S  

Research and practice in thrombosis and haemostasis 20190214 2


<h4>Background</h4>Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play only a minor role in hemostasis and is therefore an attractive anticoagulant drug target.<h4>Objectives</h4>To evaluate the safety, pharmacodynamic, and pharmacokinetic properties of BAY 1213790, a fully human immunoglobulin (Ig) G1 antibody targeting activated coagulation FXI (FXIa), in healthy men.<h4>Methods</h4>In this phase 1, single-blind, parallel-group, placebo-controlled, dose  ...[more]

Similar Datasets

| S-EPMC8518835 | biostudies-literature
| S-EPMC9320929 | biostudies-literature
| S-EPMC8866703 | biostudies-literature
2023-07-24 | GSE237965 | GEO
| S-EPMC6972670 | biostudies-literature
| S-EPMC9349145 | biostudies-literature
| S-EPMC5903252 | biostudies-literature
| S-EPMC5705193 | biostudies-literature
| S-EPMC6587432 | biostudies-literature
| S-EPMC4282310 | biostudies-literature